NEXI Projected Dividend Yield
NexImmune Inc ( OTCBB : NEXI )NexImmune is a clinical-stage biotechnology company developing an approach to immunotherapy designed to employ the body's own T cells to generate a specific immune response that mimics natural biology. Co. has two product candidates: NEXI-001 in acute myeloid leukemia, and NEXI-002 in multiple myeloma. Co.'s product candidates are adoptive T cell therapies (ACTs) that contain populations of naturally occurring CD8+ T cells that recognize a defined set of disease-relevant antigen targets. In addition to its programs using the Artificial Immune Modulation (AIM) ACT adoptive cell therapy modality, Co. is also developing an off-the-shelf injectable modality, which it refers to as AIM INJ. 20 YEAR PERFORMANCE RESULTS |
NEXI Dividend History Detail NEXI Dividend News NEXI Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |